These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 20868343)

  • 1. Recent clinical trials of mTOR-targeted cancer therapies.
    Don AS; Zheng XF
    Rev Recent Clin Trials; 2011 Jan; 6(1):24-35. PubMed ID: 20868343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug discovery targeting the mTOR pathway.
    Martelli AM; Buontempo F; McCubrey JA
    Clin Sci (Lond); 2018 Mar; 132(5):543-568. PubMed ID: 29523752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
    Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
    Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
    Wysocki PJ
    Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status and challenges associated with targeting mTOR for cancer therapy.
    Dowling RJ; Pollak M; Sonenberg N
    BioDrugs; 2009; 23(2):77-91. PubMed ID: 19489650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updates of mTOR inhibitors.
    Zhou H; Luo Y; Huang S
    Anticancer Agents Med Chem; 2010 Sep; 10(7):571-81. PubMed ID: 20812900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mammalian target of rapamycin as a target in hematological malignancies.
    Kelly KR; Rowe JH; Padmanabhan S; Nawrocki ST; Carew JS
    Target Oncol; 2011 Mar; 6(1):53-61. PubMed ID: 21499765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
    Beck JT; Ismail A; Tolomeo C
    Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. m-TOR inhibitors and their potential role in haematological malignancies.
    Calimeri T; Ferreri AJM
    Br J Haematol; 2017 Jun; 177(5):684-702. PubMed ID: 28146265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin.
    Zou Z; Chen J; Yang J; Bai X
    Curr Cancer Drug Targets; 2016; 16(4):288-304. PubMed ID: 26563881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rheb/mTOR activation and regulation in cancer: novel treatment strategies beyond rapamycin.
    Babcock JT; Quilliam LA
    Curr Drug Targets; 2011 Jul; 12(8):1223-31. PubMed ID: 21561413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
    MacKeigan JP; Krueger DA
    Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mammalian target of rapamycin: a new molecular target for breast cancer.
    Mita MM; Mita A; Rowinsky EK
    Clin Breast Cancer; 2003 Jun; 4(2):126-37. PubMed ID: 12864941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy.
    Wander SA; Hennessy BT; Slingerland JM
    J Clin Invest; 2011 Apr; 121(4):1231-41. PubMed ID: 21490404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disrupting the mTOR signaling network as a potential strategy for the enhancement of cancer radiotherapy.
    Dumont FJ; Bischoff P
    Curr Cancer Drug Targets; 2012 Oct; 12(8):899-924. PubMed ID: 22831276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of genetic alterations on mTOR-targeted cancer therapy.
    Sun SY
    Chin J Cancer; 2013 May; 32(5):270-4. PubMed ID: 23489586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy.
    Tian T; Li X; Zhang J
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30754640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: a patent review.
    Zask A; Verheijen JC; Richard DJ
    Expert Opin Ther Pat; 2011 Jul; 21(7):1109-27. PubMed ID: 21591993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer.
    Chan S
    Br J Cancer; 2004 Oct; 91(8):1420-4. PubMed ID: 15365568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mTOR signaling and drug development in cancer.
    Dancey J
    Nat Rev Clin Oncol; 2010 Apr; 7(4):209-19. PubMed ID: 20234352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.